| Li Xiaoliang,Sun Quanfu,Tuo Fei,et al.Analysis of internal exposure of staff performing 131I treatment in radiodiagnosis and radiotherapy institutions in China[J].Chinese Journal of Radiological Medicine and Protection,2025,45(6):506-511 |
| Analysis of internal exposure of staff performing 131I treatment in radiodiagnosis and radiotherapy institutions in China |
| Received:July 29, 2024 |
| DOI：10.3760/cma.j.cn112271-20240729-00286 |
| KeyWords:Individual monitoring Internal exposure 131I Nuclear medicine |
| FundProject: |
| Author Name | Affiliation | E-mail | | Li Xiaoliang | Key Laboratory of Radiological Protection and Nuclear Emergency, China CDC, National Institute for Radiological Protection, Chinese Center for Disease Control and Prevention, Beijing 100088, China | | | Sun Quanfu | Key Laboratory of Radiological Protection and Nuclear Emergency, China CDC, National Institute for Radiological Protection, Chinese Center for Disease Control and Prevention, Beijing 100088, China | | | Tuo Fei | Key Laboratory of Radiological Protection and Nuclear Emergency, China CDC, National Institute for Radiological Protection, Chinese Center for Disease Control and Prevention, Beijing 100088, China | | | Chen Weihong | School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China | | | Lu Keyi | Nuclear Medicine Department, First Hospital of Shanxi Medical University, Taiyuan 030001, China | | | Zhang Jianfeng | Key Laboratory of Radiological Protection and Nuclear Emergency, China CDC, National Institute for Radiological Protection, Chinese Center for Disease Control and Prevention, Beijing 100088, China | | | Liu Jianxiang | Key Laboratory of Radiological Protection and Nuclear Emergency, China CDC, National Institute for Radiological Protection, Chinese Center for Disease Control and Prevention, Beijing 100088, China | liujianxiang@nirp.chinacdc.cn |
|
| Hits: 155 |
| Download times: 52 |
| Abstract:: |
| Objective To investigate the number of medical institutions and staff involved in 131I diagnosis and therapy in China, and to ascertain the level of 131I activity incorporated in thyroid of medical staff performing the 131I treatment. Methods Questionnaires were used to investigate the basic information on nuclear medicine practices in all the non-military hospitals in China. Portable gamma spectrometers were used to determine and analyze the 131I activity in thyroid of the medical staff in some radioiodine treatment workplaces. The result were reported through National Radiological Health Information Platform. Results Until December 2022, there had been 959 hospitals performing clinical nuclear medicine practices in China, with a total of 10 820 medical staff. In China, there have been 623 hospitals performing 131I therapeutical procedures, accounting for 65.0% of all nuclear medicine hospitals, and 333 hospitals performing 131I treatment of thyroid cancer, accounting for 34.7%. The hospitals equipped with automated radiopharmaceutical dispenser accounted for 61.3% of the 623 hospitals. A total of 2 210 nuclear medicine staff were monitored for internal exposure in 20 provinces in 2022, with 249 (11.3%) having activities above 100 Bq and the maximum value of 2.9 × 104 Bq. A total of 426 nuclear medicine staff in four provinces were detected using HPGe detectors, with 101 (23.7%) detected to have 131I in their thyroid glands. A total of 1 748 in 17 provinces were detected using NaI or LaBr detectors, with 379 (21.2%) detected to have 131I in their thyroid glands. The detection rate of 131I in the staff was found to increase with the increased amount of 131I purchased by hospitals. The detection rate of 131I in the hosptitals having purchased the amount of 131I≥3.70 × 106 MBq in 2021 was 32.1%. This value was notably higher than in the other three groups whose purchased amount ＜3.70 × 106 MBq, with a statistically significant difference(χ2=15.46, P < 0.001). Conclusions There were great differences in the number of both hospitals and staff performing 131I treatment between different provinces in China. About one fifth of the staff in the 131I treatment workplaces could be detected to have incorporated 131I in their thyroid glands. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
